Market Place
Sourcing Support
ADMA Biologics Q1 2025 Financial Results and Business Update
07 May 2025 //
GLOBENEWSWIRE
ADMA Biologics to Report Q1 2025 Financial Results on May 7
30 Apr 2025 //
GLOBENEWSWIRE
ADMA Bio Wins FDA OK for Boosted Biologics Yield Process
28 Apr 2025 //
GLOBENEWSWIRE
ADMA Biologics Statement on Tariffs
07 Apr 2025 //
GLOBENEWSWIRE
ADMA Biologics Reports Q4, Full-Year 2024 Financials, Updates
03 Mar 2025 //
GLOBENEWSWIRE
ADMA To Participate In Raymond James Investor Conference
28 Feb 2025 //
GLOBENEWSWIRE
ADMA Biologics to Report Q4 and Full Year 2024 Results on March 3
25 Feb 2025 //
GLOBENEWSWIRE
ADMA Biologics Reports FY 2024 Revenue And Business Updates
13 Jan 2025 //
GLOBENEWSWIRE
ADMA Biologics to Participate in J.P. Morgan Healthcare Conference
07 Jan 2025 //
GLOBENEWSWIRE
ADMA Biologics Announces Partial Paydown of Senior Facility
20 Dec 2024 //
GLOBENEWSWIRE
ADMA Biologic Announce Q3` 24 Financial Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
ADMA Biologics to Report Q3 2024 Results on Nov 7, 2024
29 Oct 2024 //
GLOBENEWSWIRE
ADMA Biologics Set to Join S&P SmallCap 600 Index
17 Sep 2024 //
GLOBENEWSWIRE
ADMA Biologics To Join 2024 Cantor Global Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
14 Aug 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
01 Aug 2024 //
GLOBENEWSWIRE
ADMA Biologics Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
02 May 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces FDA Approvals for ASCENIV & BIVIGAM®
11 Mar 2024 //
GLOBENEWSWIRE
ADMA Biologics to Participate in Raymond James Institutional Investor Conference
05 Mar 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces CFO Transition
28 Feb 2024 //
GLOBENEWSWIRE
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
21 Feb 2024 //
GLOBENEWSWIRE
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results
21 Feb 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue
08 Jan 2024 //
GLOBENEWSWIRE
ADMA Bio Announces $135 Million Non-Dilutive Refinancing of Credit Facilities
18 Dec 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient
12 Dec 2023 //
GLOBENEWSWIRE
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center
16 Nov 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
ADMA Biologics to Report Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
02 Aug 2023 //
GLOBENEWSWIRE
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center
19 Jul 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces 1Q 2023 Financial Results and Provides Business Update
10 May 2023 //
GLOBENEWSWIRE
ADMA Biologics to Report 1Q 2023 Financial Results on May 10, 2023
03 May 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces Amendment to Credit Agreement
02 May 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
ADMA BioCenters Receives FDA Approval for Eighth Plasma Collection Center
08 Feb 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues
17 Jan 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces FDA Approval for ASCENIV & BIVIGAM
13 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Closing of $69 Million Public Offering
09 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Pricing of Public Offering for $60 M of Common Stock
07 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
06 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Proposed Public Offering of Common Stock
06 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Q2 Financial Results and Provides Business Update
10 Aug 2022 //
GLOBENEWSWIRE
ADMA Biologics to Report Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Addition to the Russell 2000 Index
21 Jun 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
04 May 2022 //
GLOBENEWSWIRE
ADMA Announces Live Poster Presentation and Symposium with ASCENIV at CIS 2022
01 Apr 2022 //
GLOBENEWSWIRE
FDA Approves Extended Shelf Life for ADMA`s ASCENIV & BIVIGAM from 24-36 Months
25 Mar 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Q4 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
ADMA Biologics to Report Q4 and Full Year 2021 Financial Results on March 24
21 Mar 2022 //
GLOBENEWSWIRE
ADMA Biologics: Prelim Q4 and Full Year 2021 Revenues & 2022 Business Update
19 Jan 2022 //
GLOBENEWSWIRE
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center
18 Jan 2022 //
GLOBENEWSWIRE
ADMA Biologics Provides Update on Global Intellectual Property Portfolio
09 Dec 2021 //
GLOBENEWSWIRE
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman
17 Nov 2021 //
GLOBENEWSWIRE
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening
16 Nov 2021 //
GLOBENEWSWIRE
ADMA Biologics Reports Record Third Quarter 2021 Financial Results &Highlights
10 Nov 2021 //
GLOBENEWSWIRE
